Excerpts from analyst's report
Maybank Kim Eng analyst: John Cheong
Masterstroke in China
Unorthodox masterstroke to break into China. Convinced this is right move after meetings with CCBC.
CCBC/Cordlife partnership in China mutually beneficial. 10% stake in CCBC should become more valuable.
Maintain BUY & SOTP TP of SGD1.30. Catalysts from possible maiden dividends from CCBC, better sales traction in China.
Setting record straight
We returned even more positive from meetings in Beijing with the CFO of China Cord Blood Corporation (CCBC), China’s leading cord blood bank. In our view, Cordlife’s sell-down following its CCBC convertible-note purchase and loan to Magnum Opus reflects a lack of understanding and appreciation of the motivation behind the deal and risk measures in place. We hope to set this straight.
Cordlife’s 10% stake in CCBC — 14.2% upon conversion of CBs in 2017 — should only become more valuable over time, in our view. New products from Cordlife are being pushed out via CCBC’s vast China network. We observe close working and personal relationships between the managements of both companies.
Unorthodox masterstroke to gain China foothold
While its loan to Magnum Opus was unorthodox, it was necessary to cement its relationship with CCBC. We view the loan as a proxy for a direct equity investment in CCBC. By controlling the debtor, Cordlife can control the equity part of the equation as well. Despite its mere 10% stake, Cordlife has been able to punch far above its weight.
Multi-layer risk measures in place
Auditing procedures for Chinese companies have been strengthened considerably since the Sino-Forest accounting scandal in 2011. CCBC believes this has not been sufficiently appreciated by investors. External auditors can now check bank balances independently every quarter, while budget-busting cash transfers would need the entire board’s approval and three senior signatories.
Full report here.
Full report here.
Recent story: CORDLIFE: Strong Insider Buying After Price Fall